Artificial Pancreas Device System (APDS) Market Analysis by Type (Threshold Suspended Device System, Control to Range (CTR) System, Control to Target (CTT) System), and Segment Forecasts To 2024

Published: Aug, 2016 | Pages: 96 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The global artificial pancreas device system (APDS) market is expected to reach USD 390 million by 2024, according to a new report by Grand View Research, Inc. Rising occurrence of diabetes, increasing incidence of adverse effects due to improper insulin administration, and the growing interest of industry participants in the development of innovative treatments are some vital impact rendering drivers.

As of 2014, the Centers for Disease Control stated that about 1.5 million individuals in the U.S. alone are suffering from type 1 diabetes. Furthermore, the development of sedentary lifestyles among teenagers is propelling the probability of disease development globally.

Hence, the economic burden weighing over the healthcare system due to the rising incidence of diabetes has led to an increase in the research activities and funding by government bodies across the globe. Furthermore, the introduction of information technology and its numerous applications within the healthcare industry is expected to act as boon for the APDS market.

For instance, the GlucoSitter Software used for tracking the glucose level and insulin administration in case of hypoglycemic conditions received the CE mark in 2015 at the annual conference of the Advanced Technologies & Treatments for Diabetes. The software was the first of its kind to receive regulatory approval and will be commercially available through the company DreaMed Diabetes Ltd.

Further key findings from the study suggest:

On the basis of the device type, the market has been segmented into threshold suspended device, Control to Range (CTR) System, and Control to Target (CTT) System. As of 2015, the threshold suspended device segment is expected to hold majority of the share. Medtronic's currently available, MiniMed 530G is based on this technology. However, over the forecast period, the CTT and CTR based systems are predicted to gain popularity owing to the higher automation and improved management of the disease, limiting the incidence of severe conditions among patients.

North America is expected to dominate the APDS market over the forecast period owing to the large pool of patients suffering from type 1 diabetes within the region. Furthermore, the continuous R&D activities directed towards an increasingly automated, permanent management & monitoring system for diabetes and government programs supporting research initiatives through funds and expertise is anticipated to help boost the market growth.

Along with North America, Europe is also anticipated to witness lucrative growth. Faster regulatory approvals and routine involvement of the region in conducting timely clinical trials of upcoming products are the vital impact rendering drivers. For instance, the project AP@Home was initiated by the European Union and was completed in October 2015. This project was focused on the development of a combined device capable of administering insulin and monitoring the glucose level of the patient by use of a single catheter.

However, Asia Pacific is predicted to witness the fastest growth, attributable to the presence of about 60.0% of the global population suffering from diabetes in this region. This number is expected to rise over the forecast period owing to the changing lifestyles of the younger population and the growing genetic predisposition amongst the newer generations to developing diabetes, over the past few decades.

Major industry players include Medtronic, Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics, Johnson & Johnson (Animas Corporation), and others. In July 2016, Tandem Diabetes Care, Inc. announced a collaboration with TypeZero Technologies, LLC to obtain the licensing rights for their technology. As per this collaboration, Tandem Diabetes Care, Inc. intends to incorporate the artificial pancreas technology, developed by TypeZero Technologies, LLC, into their product t:slim Insulin Pump.

 Table of Contents


Chapter 1 Research Methodology
                    1.1 Research Methodology
                    1.2 Research Scope & Assumptions
                    1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Summary
Chapter 4 Market Variables, Trends & Scope
                    4.1 Market Segmentation & Scope
                    4.2 Market Driver Analysis
                    4.3 Market Restraint Analysis
                    4.4 Penetration & Growth Prospect Mapping
                    4.5 SWOT Analysis, By Factor
                        4.5.1 Political
                        4.5.2 Economic
                        4.5.3 Technology
Chapter 5 Market Categorization 1: Device Type Estimates & Trend Analysis 
                    5.1 Device Type Movement Analysis & Market Share, 2015 & 2024
                    5.2 Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following device types:
                        5.2.1 Threshold suspended device system
                        5.2.2 CTR system
                        5.2.3 CTT system
Chapter 6 Market Categorization 2: Regional Estimates & Trend Analysis
                    6.1 Regional Movement Analysis & Market Share, 2015 & 2024
                    6.2 Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following regions:
                        6.2.1 North America
                              6.2.1.1 U.S.
                              6.2.1.2 Canada
                        6.2.2 Europe
                              6.2.2.1 UK
                              6.2.2.2 Germany
                        6.2.3 Asia Pacific
                              6.2.3.1 Japan
                              6.2.3.2 China
                        6.2.4 Latin America
                              6.2.4.1 Brazil
                              6.2.4.2 Mexico
                        6.2.5 MEA
                              6.2.5.1 South Africa
Chapter 7 Competitive Landscape
                    7.1 Strategy Framework
                    7.2 Company Profiles
                        7.2.1 Medtronic
                              7.2.1.1 Company Overview
                              7.2.1.2 Financial Performance
                              7.2.1.3 Product Benchmarking
                              7.2.1.4 Strategic Initiatives
                        7.2.2 Bigfoot Biomedical
                              7.2.2.1 Company Overview
                              7.2.2.2 Financial Performance
                              7.2.2.3 Product Benchmarking
                              7.2.2.4 Strategic Initiatives
                        7.2.3 Johnson & Johnson 
                              7.2.3.1 Company Overview
                              7.2.3.2 Financial Performance
                              7.2.3.3 Product Benchmarking
                              7.2.3.4 Strategic Initiatives
                        7.2.4 Tandem Diabetes Care, Inc.
                              7.2.4.1 Company Overview
                              7.2.4.2 Financial Performance
                              7.2.4.3 Product Benchmarking
                              7.2.4.4 Strategic Initiatives
                        7.2.5 Pancreum, Inc.
                              7.2.5.1 Company Overview
                              7.2.5.2 Financial Performance
                              7.2.5.3 Product Benchmarking
                              7.2.5.4 Strategic Initiatives
                        7.2.6 TypeZero Technologies, LLC
                              7.2.6.1 Company Overview
                              7.2.6.2 Financial Performance
                              7.2.6.3 Product Benchmarking
                              7.2.6.4 Strategic Initiatives
                        7.2.7 Beta Bionics
                              7.2.7.1 Company Overview
                              7.2.7.2 Financial Performance
                              7.2.7.3 Product Benchmarking
                              7.2.7.4 Strategic Initiatives

List of Tables


TABLE 1 North America artificial pancreasdevice systemmarket, by region, 2013 - 2024 (USD Million) 
TABLE 2 North America artificial pancreas device system market, by Device Type, 2013 - 2024 (USD Million) 
TABLE 3 U.S. artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 4 Canada artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 5 Europe artificial pancreasdevice system market, byregion, 2013 - 2024 (USD Million) 
TABLE 6 Europe artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 7 UK artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 8 Germany artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 9 Asia Pacific artificial pancreasdevice system market, by region, 2013 - 2024 (USD Million) 
TABLE 10 Asia Pacific artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 11 Japan artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 12 China artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 13 Latin America artificial pancreasdevice system market, by region 2013 - 2024 (USD Million) 
TABLE 14 Latin America artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 15 Brazil artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 16 Mexico artificial pancreasdevice system market, bydevice type, 2013 - 2024 (USD Million) 
TABLE 17 MEA artificial pancreasdevice system market, by region, 2013 - 2024 (USD Million) 
TABLE 18 MEA artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million) 
TABLE 19 South Africa artificial pancreasdevice system market, by device type, 2013 - 2024 (USD Million)